

CLAIMS

1. A pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the functions of midkine (MK) as an effective ingredient.
2. The pharmaceutical composition of claim 1, wherein the compound inhibiting the function of MK is an antisense oligonucleotide that inhibits intracellular MK protein synthesis by binding to a segment of a single-stranded mRNA transcribed from the MK gene.
3. The pharmaceutical composition of claim 1, wherein the compound inhibiting the function of MK is an antibody against the MK protein or a fragment comprising its variable region.
4. The pharmaceutical composition of claim 1, wherein angiostenosis is caused by arteriosclerosis or restenosis after PTCA surgery.
5. A method for screening a compound for the prevention or treatment of angiostenosis, comprising the steps of:
- (a) contacting MK expressed cells with a candidate compound; and,
 - (b) selecting a compound inhibiting the function of MK.
6. A pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound selected by the method of claim 5 as an effective ingredient.

Add
A1

0976356-04304